Telomir Pharmaceuticals, Inc.
A preclinical stage pharmaceutical company focused on developing and commercializing a novel small molecule, TELOMIR-1, as an oral in situ therapeutic for the treatment of human stem cells. The company is focused on the treatment of inhibiting the production of inflammatory cytokines such as IL-17 for age-related inflammatory diseases such as hemochromatosis and osteoarthritis, as well as post-chemotherapy recovery.
Overview
Overview | |
|---|---|
Country | United States |
State | Florida |
Employees | 1 |
Founded | 2021 |
Financials | |
|---|---|
Market Capitalization | 122.29M |
Revenue | |
Operating Income | |
Operating Margin | |
Net Income | -18.84M |
Ranking
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3947 / 5565 |
Sector : Healthcare | 672 / 1182 |
Industry : Biotechnology | 353 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 3769 / 5436 |
Sector : Healthcare | 465 / 1164 |
Industry : Biotechnology | 181 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 5311 / 5330 |
Sector : Healthcare | 1169 / 1174 |
Industry : Biotechnology | 663 / 667 |